Management of Dyslipidaemia in Real-world Clinical Practice: Rationale and Design of the VIPFARMA ISCP Project

Ricardo Lopez Santi, Felipe Martinez, Adrian Baranchuk, Alvaro Sosa Liprandi, Daniel Piskorz, Alberto Lorenzatti, Maria Pilar Lopez Santi, Juan Carlos Kaski, Ricardo Lopez Santi, Felipe Martinez, Adrian Baranchuk, Alvaro Sosa Liprandi, Daniel Piskorz, Alberto Lorenzatti, Maria Pilar Lopez Santi, Juan Carlos Kaski

Abstract

Dyslipidaemia plays a major role in the pathogenesis of atherosclerosis. Every year, scientific institutions publish cardiovascular prevention guidelines with updated goals and recommendations based on new evidence. However, medical barriers exist that make achieving these goals difficult and gaps between guidelines and best daily clinical practice still persist. The International Society of Cardiovascular Pharmacotherapy designed the Surveillance of Prescription Drugs in the Real World Project (VIPFARMA ISCP), a survey for physicians who manage lipid disorders in high-risk patients. Seven clusters of questions will be analysed comprising demographics, institution profile, access to continuing medical education, clinical practice profile, attitude regarding use of statins, knowledge regarding proprotein convertase subtilisin/kexin type 9 inhibitors and attitudes regarding medical decisions about triglycerides. The present study will be the first part of a larger programme and aims to shed light on barriers between lipid-lowering drug therapy recommendations in the 2019 European Society of Cardiology guidelines and clinical practice in different countries.

Keywords: Clinical practice; PCSK9 inhibitors; drug treatment; dyslipidaemia; guidelines; statins; triglycerides.

Conflict of interest statement

Disclosure: The authors have no conflicts of interest to declare.

Copyright © 2021, Radcliffe Cardiology.

Figures

Figure 1:. The VIPFARMA ISCP Project
Figure 1:. The VIPFARMA ISCP Project

References

    1. Patel N, Bhargava A, Kalra R et al. Trends in lipid, lipoproteins, and statin use among U.S. adults: Impact of 2013 cholesterol guidelines. J Am Coll Cardiol. 2019;74:2525–8. doi: 10.1016/j.jacc.2019.09.026.
    1. Libby P, Buring JE, Badimon L et al. Atherosclerosis. Nat Rev Dis Primers. 2019;5:56.. doi: 10.1038/s41572-019-0106-z.
    1. Ray KK, Corral P, Morales E, Nicholls SJ. Pharmacological lipid-modification therapies for prevention of ischaemic heart disease: current and future options. Lancet. 2019;394:697–708. doi: 10.1016/S0140-6736(19)31950-6.
    1. Lorenzatti AJ, Toth PP. New perspectives on atherogenic dyslipidaemia and cardiovascular disease. Eur Cardiol. 2020;15:e04. doi: 10.15420/ecr.2019.06.
    1. Agarwala A, Shapiro MD. Emerging strategies for the management of atherogenic dyslipidaemia. Eur Cardiol. 2020;15:e05. doi: 10.15420/ecr.2019.16.
    1. Kotseva K, De Backer G, De Bacquer D Primary prevention efforts are poorly developed in people at high cardiovascular risk: a report from the European Society of Cardiology EURObservational Research Programme EUROASPIRE V survey in 16 European countries. Eur J Prev Cardiol. 2020. epub ahead of press.
    1. Rosenson RS, Kent ST, Brown TM et al. Underutilization of high-intensity statin therapy after hospitalization for coronary heart disease. J Am Coll Cardiol. 2015;65:270–7. doi: 10.1016/j.jacc.2014.09.088.
    1. Halcox JP, Tubach F, Lopez-Garcia E et al. Low rates of both lipid-lowering therapy use and achievement of low-density lipoprotein cholesterol targets in individuals at high-risk for cardiovascular disease across Europe. PLoS One. 2015;10:e0115270. doi: 10.1371/journal.pone.0115270.
    1. Okerson T, Patel J, DiMario S et al. Effect of 2013 ACC/AHA blood cholesterol guidelines on statin treatment patterns and low-density lipoprotein cholesterol in atherosclerotic cardiovascular disease patients. J Am Heart Assoc. 2017;6:e004909. doi: 10.1161/JAHA.116.004909.
    1. Vaucher J, Marques-Vidal P, Waeber G, Vollenweider P. Population impact of the 2017 ACC/AHA guidelines compared with the 2013 ESH/ESC guidelines for hypertension management. Eur J Prev Cardiol. 2018;25:1111–3. doi: 10.1177/2047487318768938.
    1. National Institute for Health and Care Excellence. Cardiovascular disease: risk assessment and reduction, including lipid modification. London: NICE; 2016. (accessed 12 February 2021)
    1. Steen DL, Khan I, Ansell D et al. Retrospective examination of lipid-lowering treatment patterns in a real-world high-risk cohort in the UK in 2014: comparison with the National Institute for Health and Care Excellence (NICE) 2014 lipid modification guidelines. BMJ Open. 2017;7:e013255. doi: 10.1136/bmjopen-2016-013255.
    1. Galve E, Cordero A, Cequier A et al. Degree of lipid control in patients with coronary heart disease and measures adopted by physicians. REPAR study. Rev Esp Cardiol (Engl Ed) 2016;69:931–8. doi: 10.1016/j.rec.2016.02.012.
    1. Avezum A, Oliveira GBF, Lanas F et al. Secondary CV prevention in South America in a community setting: the PURE study. Glob Heart. 2017;12:305–13. doi: 10.1016/j.gheart.2016.06.001.
    1. Gupta R, Islam S, Mony P et al. Socioeconomic factors and use of secondary preventive therapies for cardiovascular diseases in South Asia: the PURE study. Eur J Prev Cardiol. 2015;22:1261–71. doi: 10.1177/2047487314540386.
    1. Danchin N, Almahmeed W, Al-Rasadi K et al. Achievement of low-density lipoprotein cholesterol goals in 18 countries outside Western Europe: the International ChoLesterol management Practice Study (ICLPS). Eur J Prev Cardiol. 2018;25:1087–94. doi: 10.1177/2047487318777079.
    1. Giugliano RP, Cannon CP, Blazing MA et al. Benefit of adding ezetimibe to statin therapy on cardiovascular outcomes and safety in patients with versus without diabetes mellitus: results from IMPROVE-IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial). Circulation. 2018;137:1571–82. doi: 10.1161/CIRCULATIONAHA.117.030950.
    1. Sabatine MS, Giugliano RP, Keech AC et al. Evolocumab and clinical outcomes in patients with cardiovascular disease. N Engl J Med. 2017;376:1713–22. doi: 10.1056/NEJMoa1615664.
    1. Bhatt DL, Steg PG, Miller M et al. Effects of icosapent ethyl on total ischemic events: from REDUCE-IT. J Am Coll Cardiol. 2019;73:2791–802. doi: 10.1016/j.jacc.2019.02.032.
    1. Halcox JP, Banegas JR, Roy C et al. Prevalence and treatment of atherogenic dyslipidemia in the primary prevention of cardiovascular disease in Europe: EURIKA, a cross-sectional observational study. BMC Cardiovasc Disord. 2017;17:160. doi: 10.1186/s12872-017-0591-5.
    1. Skulas-Ray AC, Wilson PWF, Harris WS et al. Omega-3 fatty acids for the management of hypertriglyceridemia: a science advisory from the American Heart Association. Circulation. 2019;140:e673–91. doi: 10.1161/CIR.0000000000000709.
    1. Erhardt L, Mourad JJ. Adherence to antihypertensive and lipid-lowering therapy – impact on clinical practice. Eur Cardiol. 2008;4:10–5. doi: 10.15420/ecr.2008.4.2.10.
    1. Cosentino F, Grant PJ, Aboyans V et al. 2019 ESC guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. Eur Heart J. 2020;41:255–323. doi: 10.1093/eurheartj/ehz486.
    1. Reiner Z, Sonicki Z, Tedeschi-Reiner E. Physicians’ perception, knowledge and awareness of cardiovascular risk factors and adherence to prevention guidelines: the PERCRO-DOC survey. Atherosclerosis. 2001;213:598–603. doi: 10.1016/j.atherosclerosis.2010.09.014.
    1. Schwartz LM, Woloshin S. Medical marketing in the United States, 1997-2016. JAMA. 2019;321:80–96. doi: 10.1001/jama.2018.19320.
    1. ESC Board. The future of continuing medical education: the roles of medical professional societies and the health care industry. Eur Heart J. 2019;40:1720–7. doi: 10.1093/eurheartj/ehy003.
    1. Khatib R, McKee M, Shannon H et al. Availability and affordability of cardiovascular disease medicines and their effect on use in high-income, middle-income, and low-income countries: an analysis of the PURE study data. Lancet. 2016;387:61–9. doi: 10.1016/S0140-6736(15)00469-9.
    1. GBD 2017 Causes of Death Collaborators. Global, regional, and national age-sex-specific mortality for 282 causes of death in 195 countries and territories, 1980-2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet. 2018;392:1736–88. doi: 10.1016/S0140-6736(18)32203-7.
    1. Forsetlund L, Bjørndal A, Rashidian A et al. Continuing education meetings and workshops: effects on professional practice and health care outcomes. Cochrane Database Syst Rev. 2009;2009:CD003030. doi: 10.1002/14651858.CD003030.pub2.
    1. Nissen SE. Reforming the continuing medical education system. JAMA. 2015;313:1813–4. doi: 10.1001/jama.2015.4138.
    1. Cullen MW, Geske JB, Anavekar NS et al. Reinvigorating continuing medical education: meeting the challenges of the digital age. Mayo Clin Proc. 2019;94:2501–9. doi: 10.1016/j.mayocp.2019.07.004.
    1. Raal FJ, Hovingh GK, Catapano AL. Familial hypercholesterolemia treatments: Guidelines and new therapies. Atherosclerosis. 2018;277:483–92. doi: 10.1016/j.atherosclerosis.2018.06.859.
    1. Pedro-Botet J, Ascaso JF, Blasco M et al. Triglycerides, HDL cholesterol and atherogenic dyslipidaemia in the 2019 European guidelines for the management of dyslipidaemias. Clin Investig Arterioscler. 2020;32:209–18. doi: 10.1016/j.arteri.2019.12.001.
    1. Alonso R, Perez de Isla L, Muñiz-Grijalvo O et al. Hypercholesterolaemia diagnosis and management. Eur Cardiol. 2018;13:14–20. doi: 10.15420/ecr.2018:10:2.
    1. Presta V, Figliuzzi I, Miceli F et al. Achievement of low density lipoprotein (LDL) cholesterol targets in primary and secondary prevention: Analysis of a large real practice database in Italy. Atherosclerosis. 2019;285:40–8. doi: 10.1016/j.atherosclerosis.2019.03.017.
    1. Lan NSR, Martin AC, Brett T et al. Improving the detection of familial hypercholesterolaemia. Pathology. 2019;51:213–21. doi: 10.1016/j.pathol.2018.10.015.
    1. Akyea RK, Kai J, Qureshi N et al. Sub-optimal cholesterol response to initiation of statins and future risk of cardiovascular disease. Heart. 2019;105:975–81. doi: 10.1136/heartjnl-2018-314253.
    1. Chen ST, Huang ST, Shau WY et al. Long-term statin adherence in patients after hospital discharge for new onset of atherosclerotic cardiovascular disease: a population-based study of real world prescriptions in Taiwan. BMC Cardiovasc Disord. 2019;19:62. doi: 10.1186/s12872-019-1032-4.
    1. Warden BA, Fazio S, Shapiro MD. The PCSK9 revolution: current status, controversies, and future directions. Trends Cardiovasc Med. 2020;30:179–85. doi: 10.1016/j.tcm.2019.05.007.
    1. Furtado RHM, Giugliano RP. What lessons have we learned and what remains to be clarified for PCSK9 Inhibitors? A review of FOURIER and ODYSSEY outcomes trials. Cardiol Ther. 2020;9:59–73. doi: 10.1007/s40119-020-00163-w.
    1. Giugliano RP, Mach F, Zavitz K et al. Cognitive function in a randomized trial of evolocumab. N Engl J Med. 2017;377:633–43. doi: 10.1056/NEJMoa1701131.
    1. Bhatt DL, Steg PG, Miller M et al. Cardiovascular risk reduction with icosapent ethyl for hypertriglyceridemia. N Engl J Med. 2019;380:11–22. doi: 10.1056/NEJMoa1812792.

Source: PubMed

Sponsors en medewerkers

Medische omstandigheden

Geneesmiddelinterventies

3
Abonneren